EMBC vs MRK · P/E 12, rev $1.08B vs P/E 33, rev $16.61B
Embecta Corp (EMBC) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
Embecta Corp (EMBC) is a medical instruments & supplies company listed on US.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Robert M. Davis J.D..
Latest reported EMBC revenue for 2025-09-30 was $1.08B. Net income was $95.4M. Revenue was down 3.8% from 2024-09-30 to 2025-09-30. EMBC currently screens at market cap $609.6M and trailing P/E 11.7.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
EMBC currently screens at market cap $609.6M and trailing P/E 11.7. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the EMBC and MRK stock pages for the full models.
Not investment advice.